20

A new study from the University of Bern reveals that GLP-1 receptor agonists, a class of drugs that includes semaglutide (Ozempic, Wegovy), offer more than just weight loss benefits. Researchers found that these medications also enhance mental wellbeing and quality of life, outperforming insulin and other antidiabetic drugs. The effects are particularly noticeable in individuals without pre-existing mental health conditions.

Mental Health Benefits Across the Board

The study, presented at the European Congress on Obesity in Malaga, Spain, highlights that GLP-1 drugs provide significant benefits not only for the general population but also for those with serious mental health disorders. Individuals with conditions like schizophrenia, bipolar disorder, and major depression showed improvements in mental health outcomes after using these drugs. The research involved five separate studies, with participants who were on antipsychotic or antidepressant medications reporting better mental health without an increased risk of new psychiatric conditions or hospitalizations.

How GLP-1 Drugs Support Mood Regulation

According to the lead researcher, the antidepressant and anti-anxiety effects of GLP-1 receptor agonists may stem from their anti-inflammatory and antioxidant properties. These drugs may help reduce neuroinflammation, a condition linked to several mental health disorders. The researcher emphasized the importance of these findings for patients with severe mental illnesses, who are at an elevated risk of obesity—three times more likely than the general population.

Raising Awareness and Access to Treatment

The study’s findings have sparked interest from mental health experts who are now calling for better access to these medications, especially for individuals struggling with mental health issues. Experts stress the need for careful clinical assessment and monitoring when prescribing these medications. They highlighted the potential benefits they could offer to those who face both physical and mental health challenges.

Addressing Broader Health Risks

A representative from a mental health organization welcomed the research but warned about the broader health risks faced by patients with psychiatric conditions. Many individuals with mental health issues die 20 years earlier than the general population, often due to preventable illnesses such as diabetes, which are worsened by the side effects of psychiatric medications. The representative urged caution and emphasized the importance of long-term treatments that address both mental and physical health without causing harmful side effects. They also mentioned the need for careful medical supervision, particularly for patients at risk of developing eating disorders.

A Growing Focus on Mental Health Across Europe

This research comes at a time when mental health continues to be a major concern in Europe. In England and Wales, approximately 13-15% of working-age individuals are affected by mental health issues, with 2 million people in contact with mental health services as of December 2024. As evidence supporting the benefits of weight-loss medications grows, particularly in relation to mental health, there is growing optimism that these treatments could offer new therapeutic pathways—especially for vulnerable populations.